[go: up one dir, main page]

WO2018136163A3 - Polypeptides de fusion apoa-1 en tandem - Google Patents

Polypeptides de fusion apoa-1 en tandem Download PDF

Info

Publication number
WO2018136163A3
WO2018136163A3 PCT/US2017/065078 US2017065078W WO2018136163A3 WO 2018136163 A3 WO2018136163 A3 WO 2018136163A3 US 2017065078 W US2017065078 W US 2017065078W WO 2018136163 A3 WO2018136163 A3 WO 2018136163A3
Authority
WO
WIPO (PCT)
Prior art keywords
fusion polypeptides
apoa
polypeptide
disclosed
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/065078
Other languages
English (en)
Other versions
WO2018136163A2 (fr
Inventor
Martha S. Hayden-Ledbetter
Jeffrey A. Ledbetter
Vince Montes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theripion Inc
Original Assignee
Theripion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theripion Inc filed Critical Theripion Inc
Publication of WO2018136163A2 publication Critical patent/WO2018136163A2/fr
Publication of WO2018136163A3 publication Critical patent/WO2018136163A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L'invention concerne des compositions et des procédés relatifs aux polypeptides de fusion ApoA-1. Dans des modes de réalisation particuliers, les polypeptides de fusion comprennent des premier et second segments polypeptidiques reliés en tandem par l'intermédiaire d'un lieur, chaque segment correspondant à un polypeptide ApoA-1 ou un mimétique d'ApoA-1. Les polypeptides de fusion peuvent également comprendre un domaine de dimérisation ou un domaine qui se lie spécifiquement au récepteur Fc néonatal (par exemple, une région Fc ou une albumine), qui est typiquement lié côté carboxyle-terminal au second segment polypeptidique par l'intermédiaire d'un lieur flexible. Dans certains modes de réalisation, le polypeptide de fusion comprend en outre un segment polypeptidique supplémentaire qui confère une seconde activité biologique (par exemple, RNase, paraoxonase, acétylhydrolase du facteur d'activation plaquettaire, protéine de transfert d'ester de cholestérol, lécithine-cholestérol acyltransférase ou polypeptide qui se lie de manière spécifique à l'amyloïde bêta). L'invention concerne également des protéines dimériques comprenant des premier et second polypeptides de fusion ApoA-1 comprenant un domaine de dimérisation tel que décrit dans la présente invention. Les polypeptides de fusion et les protéines dimériques sont utiles dans des méthodes thérapeutiques.
PCT/US2017/065078 2016-12-09 2017-12-07 Polypeptides de fusion apoa-1 en tandem Ceased WO2018136163A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662432128P 2016-12-09 2016-12-09
US62/432,128 2016-12-09
US201762467288P 2017-03-06 2017-03-06
US62/467,288 2017-03-06

Publications (2)

Publication Number Publication Date
WO2018136163A2 WO2018136163A2 (fr) 2018-07-26
WO2018136163A3 true WO2018136163A3 (fr) 2018-09-27

Family

ID=62152610

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/065078 Ceased WO2018136163A2 (fr) 2016-12-09 2017-12-07 Polypeptides de fusion apoa-1 en tandem

Country Status (1)

Country Link
WO (1) WO2018136163A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114578046A (zh) * 2020-11-30 2022-06-03 广东菲鹏生物有限公司 新型冠状病毒(SARS-CoV-2)抗体检测试剂
CA3206901A1 (fr) 2021-02-19 2022-08-25 Theripion, Inc. Polypeptides de fusion paraoxonase et compositions et methodes associees

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038609A2 (fr) * 2000-11-10 2002-05-16 Proteopharma Aps Analogues d'apolipoproteine

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE54046B1 (en) 1981-08-25 1989-05-24 Celltech Ltd Expression vectors
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en) 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4661454A (en) 1983-02-28 1987-04-28 Collaborative Research, Inc. GAL1 yeast promoter linked to non galactokinase gene
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
CA1280080C (fr) 1984-12-06 1991-02-12 Jacques Oberto Promoteurs dans l'expression de genes etrangers chez la levure, plasmides les renfermant et leur utilisation dans la production de polypeptides
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5063154A (en) 1987-06-24 1991-11-05 Whitehead Institute For Biomedical Research Pheromone - inducible yeast promoter
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
US5298418A (en) 1991-09-16 1994-03-29 Boyce Thompson Institute For Plant Research, Inc. Cell line isolated from larval midgut tissue of Trichoplusia ni
JPH08502646A (ja) 1992-09-14 1996-03-26 ファイザー・インコーポレイテッド 不死化細胞およびその使用
WO1994012520A1 (fr) 1992-11-20 1994-06-09 Enzon, Inc. Segment de liaison pour polypeptides fusionnes lies
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5641655A (en) 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
US5955349A (en) 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
US5716808A (en) 1995-11-09 1998-02-10 Zymogenetics, Inc. Genetic engineering of pichia methanolica
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
US5854039A (en) 1996-07-17 1998-12-29 Zymogenetics, Inc. Transformation of pichia methanolica
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
WO2002094852A2 (fr) 2001-05-24 2002-11-28 Zymogenetics, Inc. Proteines hybrides taci-immunoglobuline
EP1664116A4 (fr) 2003-08-22 2009-06-03 Biogen Idec Inc Anticorps ameliores possedant une fonction d'effecteur modifiee et procedes de fabrication associes
WO2005063815A2 (fr) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Variants de polypeptides de liaison au recepteur fc$g(g) et procede apparentes
WO2005047327A2 (fr) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Variants de polypeptide se liant au recepteur fc neonatal (fcrn), proteines de liaison fc dimeres et techniques associees
US20070111281A1 (en) 2005-05-09 2007-05-17 Glycart Biotechnology Ag Antigen binding molecules having modified Fc regions and altered binding to Fc receptors
SG194680A1 (en) 2011-04-29 2013-12-30 Univ Washington Therapeutic nuclease compositions and methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038609A2 (fr) * 2000-11-10 2002-05-16 Proteopharma Aps Analogues d'apolipoproteine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SEGREST J P ET AL: "STRUCTURE AND FUNCTION OF APOLIPOPROTEIN A-I AND HIGH-DENSITY LIPOPROTEIN", CURRENT OPINION IN LIPIDO, LIPPINCOTT WILLIAMS AND WILKINS, LONDON, GB, vol. 11, no. 2, 1 April 2000 (2000-04-01), pages 105 - 115, XP009030702, ISSN: 0957-9672, DOI: 10.1097/00041433-200004000-00002 *
SHU-CHEN LU ET AL: "An apoA-I mimetic peptibody generates HDL-like particles and increases alpha-1 HDL subfraction in mice", JOURNAL OF LIPID RESEARCH, vol. 53, no. 4, 1 April 2012 (2012-04-01), US, pages 643 - 652, XP055484725, ISSN: 0022-2275, DOI: 10.1194/jlr.M020438 *

Also Published As

Publication number Publication date
WO2018136163A2 (fr) 2018-07-26

Similar Documents

Publication Publication Date Title
EP2352523A4 (fr) Anticorps anti-cd19 améliorés
JO3658B1 (ar) بروتينات اندماج
BR112021017399A2 (pt) Proteína de fusão bifuncional e uso farmacêutico da mesma
TW201613958A (en) MIC-1 fusion proteins and uses thereof
MX2022015847A (es) Proteinas de union a cd123 y composiciones y metodos relacionados.
HK1200842A1 (en) Proteins with improved half-life and other properties
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
MX2015000397A (es) Complejo del factor viii con xten y proteina del factor von willebrand, y sus usos.
WO2013003649A3 (fr) Polypeptides de fusion de domaines d'une protéine acide du lactosérum et procédés d'utilisation de ceux-ci
PH12018502451A1 (en) Brain delivery protein
WO2006104677A3 (fr) Anticorps se liant a ov064 et leurs methodes d'utilisation
MX2019009817A (es) Anticuerpos anti-tau y metodos de uso de los mismos.
WO2015175874A3 (fr) Molécules présentant une altération de liaison de récepteur fc néonatal ayant des propriétés thérapeutiques et diagnostiques améliorées
PL397167A1 (pl) Przeciwnowotworowe bialko fuzyjne
MX350962B (es) Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion.
WO2015031673A3 (fr) Conjugués comportant des régions fc modifiées pour cibler le snc et méthodes pour les utiliser
MX388977B (es) Proteinas de fusion de interleucina 2/receptor de interleucina-2 alfa y metodos de uso.
WO2013181087A3 (fr) Complexes multimères présentant une meilleure stabilité in vivo, une meilleure pharmacocinétique et une meilleure efficacité
WO2007070671A3 (fr) Procedes therapeutiques pour l'inhibition de croissance tumorale avec des antagonistes dll4
EA201791238A1 (ru) Способы и композиции, в которых используются варианты полипептидов klotho
MX389878B (es) Proteinas quimericas de factor viii y usos de estas.
JP2017501728A5 (fr)
BR112012006492A2 (pt) proteína de fusão de anticorpo multivalente, e, ligação de albumina
MA38797A1 (fr) Protéine de fusion thérapeutique
BR112013020274A2 (pt) substitutos de proteínas pós-traducionalmente modificadas e usos dos mesmos

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17870650

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17870650

Country of ref document: EP

Kind code of ref document: A2